Acute Renal Injury

  • Jesse Goldman
  • James P. Reichart
  • Ll. Armando Samuels
  • Ubaldo J. Martin


After studying this chapter, you should be able to: Understand the pathophysiology of acute kidney injury (AKI). Recognize factors associated with the development and worsening of AKI. Elicit a concise, pertinent history and conduct a targeted physical exam in patients with acute kidney disease. Interpret urinary sediment and urinary index results. Formulate a differential diagnosis of AKI based upon history, physical findings, and laboratory data.Recognize the types of current treatment modalities and their limitations in AKI.


Glomerular Filtration Rate Renal Replacement Therapy Acute Kidney Injury Intensive Care Unit Patient Atrial Natriuretic Peptide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Chino S, Kellum J, Bellomo R, et al. Acute renal failure in critically ill patients – a multinational, multicenter study. JAMA. 2005;294:813-818.CrossRefGoogle Scholar
  2. 2.
    Abusaif NY, Tolba YA, Heap M, et al. The outcome of acute renal failure in the intensive care unit according to the RIFLE: model applicability, sensitivity, and predictability. Am J Kidney Dis. 2005;46:1038-1048.CrossRefGoogle Scholar
  3. 3.
    Hoste EAJ, Clermont G, Kersten A, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care. 2006;10:R73-R83.PubMedCrossRefGoogle Scholar
  4. 4.
    Waikar SS, Curhan GC, Wald R, et al. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol. 2006;17:1143-1150.PubMedCrossRefGoogle Scholar
  5. 5.
    Goss CH, Brower RG, Hudson LD, et al. Incidence of acute lung injury in the United States. Crit Care Med. 2003;31:1607-1611.PubMedCrossRefGoogle Scholar
  6. 6.
    Levy EM et al. The effect of acute renal failure on mortality. JAMA. 1996;275(19):1489-1494.PubMedCrossRefGoogle Scholar
  7. 7.
    Rudnick MR et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int. 1995;47(1):254-261.PubMedCrossRefGoogle Scholar
  8. 8.
    Brenner BM, ed. Brenner and Rector. The Kidney. 8th ed. Philadelphia PA: Saunders; 2007.Google Scholar
  9. 9.
    Cunningham PN et al. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor – 1 in the kidney. J Immunol. 2002;168:5817-5823.PubMedGoogle Scholar
  10. 10.
    Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Intl. 2002;62:539-549.CrossRefGoogle Scholar
  11. 11.
    Schrier RW, Wang W, Poole B, Mitra A. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest. 2004;114:5-14.PubMedGoogle Scholar
  12. 12.
    Lameire N, Vanholder R. Pathophysiolgic features and prevention of human and experimental acute tubular necrosis. J Am Soc Nephrol. 2001;12:s20-s32.PubMedGoogle Scholar
  13. 13.
    Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int. 2004;66:480.PubMedCrossRefGoogle Scholar
  14. 14.
    Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet. 2005;365:417-430.PubMedGoogle Scholar
  15. 15.
    Carvounis CP, Nisar S, Guro-Razuman S. Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure. Kidney Int. 2002;62:2223.PubMedCrossRefGoogle Scholar
  16. 16.
    Pepin MN, Bouchard J, Legault L, Ethier J. Diagnostic performance of fractional excretion of urea and fractional excretion of sodium in the evaluations of patients with acute kidney injury with or without diuretic treatment. Am J Kidney Dis. 2007;50:566.PubMedCrossRefGoogle Scholar
  17. 17.
    Steinhauslin F, Burnier M, Magnin JL, et al. Fractional excretion of trace lithium and uric acid in acute renal failure. J Am Soc Nephrol. 1994;4:1429.PubMedGoogle Scholar
  18. 18.
    Lauschke A, Teichgraber UK, Frei U, Eckardt KU. ‘Low-dose’ dopamine worsens renal perfusion in patients with acute renal failure. Kidney Int. 2006;69:1669-1674.PubMedCrossRefGoogle Scholar
  19. 19.
    Bellomo R et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomized trial. ANZICS Clinical Trials Group. Lancet. 2000;56:2139-2143.Google Scholar
  20. 20.
    Mehta RL et al. PICARD Study Group: diuretics, mortality and nonrecovery of renal function in acute renal failure. JAMA. 2002;288:2547-2553.PubMedCrossRefGoogle Scholar
  21. 21.
    Uchino S et al. Beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators: diuretics and mortality in acute renal failure. Crit Care Med. 2004;32:1669-1677.PubMedCrossRefGoogle Scholar
  22. 22.
    Cantarovich F et al. High-Dose Furosemide In Acute Renal Failure Study Group: high-dose furosemide for established ARF: a prospective, randomized double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis. 2004;44:402-409.PubMedGoogle Scholar
  23. 23.
    Ho KM, Sheridan DJ. Meta-analysis of furosemide to prevent or treat acute renal failure. BMJ. 2006;333:420-426.PubMedCrossRefGoogle Scholar
  24. 24.
    Better OS et al. Mannitol therapy revisited (1940-1997). Kidney Int. 1997;52:3886-3894.CrossRefGoogle Scholar
  25. 25.
    Lewis J et al. Atrial natriuretic factor in oligyric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis. 2000;36:797-774.CrossRefGoogle Scholar
  26. 26.
    Colucci WS et al. Intravenous Nesiritide, a natriuretic peptide in the treatment of decompensated CHF. N Engl J Med. 2000;343:246-253.PubMedCrossRefGoogle Scholar
  27. 27.
    Sackner-Berstein JD et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure. A pooled analysis of randomized controlled trials. JAMA. 2005;293:1900-1905.CrossRefGoogle Scholar
  28. 28.
    Marenzi G et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44:1780-1785.PubMedCrossRefGoogle Scholar
  29. 29.
    Navaneethan SD et al. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2009;53:617-627.PubMedCrossRefGoogle Scholar
  30. 30.
    Birck R et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362:598-603.PubMedCrossRefGoogle Scholar
  31. 31.
    Fine DM, Gelber AC, Melamed ML, Lin JC, Zhang L, Eustace JA. Risk factors for renal failure among 72 consecutive patients with rhabdomyolysis related to illicit drug use. Am J Med. 2004;117:607-610.PubMedCrossRefGoogle Scholar
  32. 32.
    Sever MS, Vanholder R, Lameire N. Management of crush-related injuries after disasters. N Engl J Med. 2006;354:1052-1063.PubMedCrossRefGoogle Scholar
  33. 33.
    Brown CV, Rhee P, Chan L, Evans K, Demetriades D, Velmahos GC. Preventing renal failure in patients with rhabdomyolysis: do bicarbonate and mannitol make a difference? J Trauma. 2004;56:1191-1196.PubMedCrossRefGoogle Scholar
  34. 34.
    Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001;60:804.PubMedCrossRefGoogle Scholar
  35. 35.
    Joannidis M. Drug-induced renal failure in the ICU. Int J Artif Organs. 2004;27:1034-1042.PubMedGoogle Scholar
  36. 36.
    Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter Baumanii. Clin Infect Dis. 1999;28:1008.PubMedCrossRefGoogle Scholar
  37. 37.
    Chambers HF. Aminoglycosides. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill; 2006.Google Scholar
  38. 38.
    Bates DW, Su L, Yu DT, et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int. 2001;60:1452.PubMedCrossRefGoogle Scholar
  39. 39.
    Huerta C, Castellsague J, Varas-Lorenzo C, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005;45:531.PubMedCrossRefGoogle Scholar
  40. 40.
    Sawyer MH, Webb DE, Balow JE, Straus SE. Acyclovir-induced renal failure. Clinical course and histology. Am J Med. 1988;84:1067.PubMedCrossRefGoogle Scholar
  41. 41.
    Tashima KT, Horowitz JD, Rosen S. Indinavir nephropathy.N Engl J Med. 1997;336:138.PubMedCrossRefGoogle Scholar
  42. 42.
    de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis. 2000;35:333.PubMedCrossRefGoogle Scholar
  43. 43.
    Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer. 1977;39:1362.PubMedCrossRefGoogle Scholar
  44. 44.
    Portilla D, Kaushal GP, Basnakian AG. Recent progress in the pathophysiology of acute renal failure. In: Runge MS, Patterson C, eds. Principles of Molecular Medicine. 2nd ed. Totawa, NJ: Humana; 2006:643-649.CrossRefGoogle Scholar
  45. 45.
    Kjellstrand CM, Campbell DC, von Hartitzsch B, Buselmeier TJ. Hyperuricemic acute renal failure. Arch Intern Med. 1974;133:349.PubMedCrossRefGoogle Scholar
  46. 46.
    Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener’s granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116:488.PubMedGoogle Scholar
  47. 47.
    Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic antibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7:33.PubMedGoogle Scholar
  48. 48.
    Pusey CD. Anti-glomerular basement membrane disease. Kidney Int. 2003;64:1535.PubMedCrossRefGoogle Scholar
  49. 49.
    Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134:1033.PubMedGoogle Scholar
  50. 50.
    Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001;60:831.PubMedCrossRefGoogle Scholar
  51. 51.
    Allford SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol. 2003;120:556.PubMedCrossRefGoogle Scholar

Additional Reading

  1. Claudio R, Rinaldo B, John Kellum A. Acute Kidney Injury. Basel: Karger; 2007.Google Scholar
  2. Briglia A, Paganini E. Acute renal failure in the intensive care unit: therapy overview, patient risk stratification, complications of renal replacement, and special circumstances. Clin Chest Med. 1999;20:347-366.PubMedCrossRefGoogle Scholar
  3. Gesualdo L. Acute renal failure in critically ill patients. Intensive Care Med. 1999;25:1188-1190.PubMedCrossRefGoogle Scholar
  4. Kribben A, Edelstein GL. Pathophysiology of acute renal failure. J Nephrol. 1999;12(Suppl 2):S142-S151.PubMedGoogle Scholar
  5. Meyer MM. Renal replacement therapies. Crit Care Med. 2000;16:29-58.Google Scholar
  6. Wagener O, Lieske J. Molecular and cell biology of acute renal failure: new therapeutic strategies. New Horiz. 1995;3:634-649.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Jesse Goldman
    • 1
  • James P. Reichart
    • 2
  • Ll. Armando Samuels
    • 3
  • Ubaldo J. Martin
    • 4
  1. 1.Department of Medicine, Section of NephrologyTemple University School of MedicinePhiladelphiaUSA
  2. 2.Department of NephrologyTemple University School of MedicinePhiladelphiaUSA
  3. 3.Department of MedicineTemple University School of MedicinePhiladelphiaUSA
  4. 4.Division of Pulmonary and Critical Care MedicineTemple University School of MedicinePhiladelphiaUSA

Personalised recommendations